Injection Devices for Biological Drugs Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Schott AG, ELI Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceutical

Global Injection Devices for Biological Drugs Market is expected to grow at a significant CAGR during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Injectable Devices for Biological Drugs Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/injection-devices-for-biological-drugs-market?sg

Key Players: Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, ELI Lilly and Company, Sandoz (Novartis AG), Terumo Corporation, Teva Pharmaceutical Industries Ltd. and Crossject.

USA - Industry Latest News:

✅ Merck's Subcutaneous Keytruda Qlex Launched
On September 19, 2025, the FDA approved Merck's subcutaneous version of Keytruda, branded as Keytruda Qlex, offering faster administration and improved patient convenience.

✅ Johnson & Johnson Acquires Intra-Cellular Therapies
On October 10, 2025, Johnson & Johnson announced its $14.6 billion acquisition of Intra-Cellular Therapies, enhancing its neuroscience portfolio.

Japan - Industry Latest News:

✅ Biocon and Yoshindo Launch Ustekinumab BS
On May 21, 2025, Biocon Biologics and Yoshindo launched Ustekinumab BS Subcutaneous Injection in Japan for treating psoriasis vulgaris and psoriatic arthritis.

✅ Alvotech's Biosimilar Approvals in Japan
On September 19, 2025, Alvotech announced the marketing approval of three new biosimilars in Japan, expanding its presence in the Japanese market.

Korea - Industry Latest News:

✅ Celltrion Launches Global Open Innovation
On September 17, 2025, Celltrion launched a global open innovation program in partnership with Seoul Bio Hub to support U.S. biotech startups in entering the Asian market.

✅ Korean Biopharma Firms at BIO USA 2025
On June 9, 2025, Korean biopharma firms showcased their innovations at BIO USA 2025, highlighting advancements in drug delivery systems and AI-driven operational systems.

Europe - Industry Latest News:

✅ Sandoz Launches PYZCHIVA® Autoinjector
On May 21, 2025, Sandoz launched PYZCHIVA® (ustekinumab) autoinjector in Europe, the first ustekinumab biosimilar available in an autoinjector format.

✅ First Ranibizumab Biosimilar Pre-filled Syringe in Europe
On October 21, 2025, the first ranibizumab biosimilar pre-filled syringe, Ranivisio®, was launched in France, with plans for a broader European rollout.

Growth Forecast Projected:

The Global Injectable Devices for Biological Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Injectable Devices for Biological Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=injection-devices-for-biological-drugs-market?sg

Key Segments:

By Type of product (Glass material, Plastic material)

By Site of administration (Skin, Circulatory/Musculoskeletal System, Organs, Central Nervous System)

By Usability (Reusable Pen Injectors, Disposable Pen Injectors)

By Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Aesthetic Treatment, Other clinical applications)

By End-user (Hospitals and Clinics, Home Care Settings, Others)

By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Injectable Devices for Biological Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Injectable Devices for Biological Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/injection-devices-for-biological-drugs-market?sg

FAQ's

Q1: Which regions are dominating the Injection Devices for Biological Drugs market and which are fastest-growing?

A: North America Region Holds the Largest Market Share of the Global Injection Devices for Biological Drugs Market.

Q2: How fast is the Injectable Devices for Biological Drugs Market growing?

A: Injection Devices for Biological Drugs Market size is expected to grow at a significant CAGR during the forecast period 2024-2031.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/injection-devices-for-biological-drugs-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.